Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

61.09 -1.25 (-2.01%)
Streaming Delayed Price Updated: 10:27 AM EST, Mar 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
87 88 Next >
News headline image
IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗
The founder criticized traditional chemotherapy approaches from Amgen and Bristol Myers and hyped up the mechanism behind Anktiva. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
News headline image
How to Spot Winning Innovation ↗
Author Lorraine Marchand stops by to chat. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
FourWorld Takes a Major Swing on Sable Offshore (SOC), Buying 8 Million Shares ↗
Specializing in offshore oil and gas, Sable Offshore Corp. operates three platforms and an onshore facility across 16 federal leases. 
Via The Motley Fool
Topics Energy Lawsuit
Bristol-Myers Squibb Co (NYSE:BMY) Offers a High Yield and Durable Dividend for Income Investors ↗
Via Chartmill
News headline image
Big Pharma Dividend Stock BMY Could Help Turn $100,000 Into a Seven‑Figure Retirement ↗
Bristol Myers Squibb has an attractive 4% yield and a strong dividend history. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
From Bristol Myers Squibb
Via Business Wire
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total... 
Via MarketMinute
Topics Intellectual Property
News headline image
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
3 Reasons to Avoid BMY and 1 Stock to Buy Instead
Over the past six months, Bristol-Myers Squibb has been a great trade, beating the S&P 500 by 22.8%. Its stock price has climbed to $61.33, representing a healthy 30.1% increase. This was partly due to... 
Via StockStory
Topics Stocks
News headline image
Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference
From Bristol Myers Squibb
Via Business Wire
News headline image
European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO
In a landmark decision for the cardiovascular treatment landscape, the European Commission (EC) officially granted marketing authorization to Cytokinetics, Inc. (Nasdaq: CYTK) on February 17, 2026, for... 
Via MarketMinute
Topics Intellectual Property
News headline image
Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia
From Bristol Myers Squibb
Via Business Wire
News headline image
2 Large-Cap Stocks on Our Buy List and 1 That Underwhelm
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth... 
Via StockStory
News headline image
Down 25%, Should You Buy the Dip on Bristol Myers Squibb? ↗
The pharma industry's dreaded patent cliff is a key driver of the stock's decline. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Incredibly Cheap Dividend Stocks to Buy Now ↗
Yes, there are bargains out there for investors seeking income-paying stocks. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Stocks to Buy and Hold for 2026 and Beyond ↗
Any of these three pharmaceutical titans could move the needle in your portfolio. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
Cytokinetics Secures Triple Crown: EU Approval of MYQORZO Solidifies Global Reach in Cardiovascular Market
Cytokinetics, Inc. (Nasdaq: CYTK) has officially cleared its final major regulatory hurdle for its flagship heart failure drug, MYQORZO (aficamten), receiving marketing authorization from the European... 
Via MarketMinute
News headline image
ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA
As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire... 
Via Finterra
Topics Lawsuit
News headline image
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
News headline image
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that... 
Via MarketMinute
Topics Intellectual Property
News headline image
The 5 Most Interesting Analyst Questions From Bristol-Myers Squibb’s Q4 Earnings Call
Bristol-Myers Squibb’s fourth quarter saw continued momentum in its growth portfolio, which management credited as the primary driver behind the company’s positive results. CEO Christopher Boerner... 
Via StockStory
Topics Earnings
News headline image
Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the... 
Via Finterra
Topics Economy Intellectual Property
News headline image
The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff
The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a... 
Via Finterra
Topics ETFs Economy Initial Public Offering
News headline image
BMY Q4 Deep Dive: Growth Portfolio Offsets Legacy Pressure, Pipeline Readouts in Focus
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 1.4% year on year to $12.5 billion. The company’s full-year revenue... 
Via StockStory
News headline image
Why Bristol Myers Squibb Stock Topped the Market Today ↗
At the end of last year, the company did particularly well with its lineup of newer medications. 
Via The Motley Fool
News headline image
Bristol Myers (BMY) Q4 2025 Earnings Transcript ↗
Bristol Myers (BMY) Q4 2025 Earnings Transcript 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
87 88 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.